Navigation Links
Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
Date:12/7/2010

ORLANDO, Fla., Dec. 7, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer (NSCLC).

After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients who received ALD518 experienced hemoglobin level increases from less than 11 g/dL to more than 12 g/dL, while no patients receiving placebo experienced this increase. In addition, patients who received ALD518 had an average lean body mass loss of 0.19 kg, compared to an average loss of 1.5 kg in those who received placebo. Additional symptoms of the disease such as fatigue were also reduced in patients who received ALD518.

The data was presented by Michael Schuster, M.D., director of the hematologic malignancy program at Stony Brook University Medical Center, at the annual meeting of the American Society of Hematology. The presentation, titled "Inhibition of Interleukin-6 (IL-6) Reverses Anemia In Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial," took place on Monday, December 6.

"The anemia of chronic disease that is seen in cancer patients is in large part due to IL-6 stimulation of hepcidin, resulting in reduced plasma iron levels," said Dr. Schuster. "Given the recent safety concerns over the use of ESAs, alternative therapeutic approaches that target IL-6, such as ALD518, would be very desirable and could potentially reduce the requirement for transfusions in this patient population."

Randall Schatzman, Ph.D., president and chief executive officer of Alder Biopharmaceuticals, added, "We continue to be encouraged by strong clinical data from ALD518 in the areas of cancer, cancer supportive care and cancer anemia. We look forward to continuing our clinical investigation in these areas in the coming year."

About Alder BiopharmaceuticalsAlder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. ALD518 is an investigational monoclonal antibody to the pro-inflammatory cytokine IL-6 that is being developed by Bristol-Myers Squibb for autoimmune indications. In addition to Bristol-Myers Squibb, partners include Merck and Genmab. For more information, visit www.alderbio.com.Media Contact: Ian Stone or David SchullRusso PartnersTel: +1 619-528-2220ian.stone@russopartnersllc.comdavid.schull@russopartnersllc.com
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... , April 18, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at a CAGR ... Global Arthroscopy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider of ... management module. Using this new feature, sleep physicians can now predict the likelihood ... positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The ...
(Date:4/24/2017)... ... , ... Emmanuel College is introducing enhancements to its RN-to-BSN ... the fall of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a ... for as little as $14,528. These changes will enable nurses to complete their degree ...
(Date:4/24/2017)... Houston, TX (PRWEB) , ... April 24, 2017 , ... ... Holocaust Memorial Museum today to honor the victims of the Holocaust and Nazi persecution, ... remembrance ceremonies at Hadamar and Auschwitz on its CMATH Champions trip to Germany and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the ... Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than ... marketer in the last 25 years. , Now, due to changes in the broadcast ...
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African company ... available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional products. ... in ancient India and Siam. It spread across Asia and Africa quickly, and today ...
Breaking Medicine News(10 mins):